This website is intended for healthcare professionals only

Overview of NICE Technology Appraisal 375: adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Disclaimer: Information intended for healthcare professionals only. This supplement has been developed and funded by Bristol-Myers Squibb. Bristol-Myers Squibb commissioned the production of the supplement. The content has been checked by Bristol-Myers Squibb for factual accuracy, to ensure it is fair and balanced, and to ensure its compliance with appropriate regulations. The NICE guidance and content provided on pp.3–5 are reproduced with permission of NICE. Copyright in the guidance rests with NICE, and it may be freely reproduced for educational and not-for-profit purposes. No reproduction by, or for, commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE. The content included in this supplement only displays the concise technology appraisal; readers are strongly advised to refer to the full appraisal at and to current NICE guidance on rheumatoid arthritis at: The prescribing information on page 7 and the advertisement feature on page 8 were provided by Bristol-Myers Squibb.

Visit our NEW site!

Guidelines for Nurses provides current, credible summaries and feature articles developed especially for nurses.